Confo Therapeutics enters into collaboration agreement with Daiichi Sankyo to discover novel medicines for CNS diseases
30 March 2023
Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design
Confo to receive upfront and milestone payments totaling € 168 million
Tiered royalties payable to Confo on net sales from resulting products
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement with Daiichi Sankyo (TSE: 4568) for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Under the terms of the agreement, Confo will lead the discovery process deploying its GPCR platform to generate lead series of small molecule compounds. Daiichi Sankyo has an exclusive option to acquire a worldwide exclusive license for the resulting compounds and advance them towards clinical development and commercialization. Confo has the potential to receive upfront payments, development and commercial milestones totaling € 168 million and royalties.
Cedric Ververken, CEO of Confo Therapeutics said :
Daiichi Sankyo has historically been at the forefront of leveraging innovative technologies to develop novel medicines. We are excited by this collaboration in which we will be using Confo’s expertise and platform to pursue a previously undruggable GPCR target in an area of high unmet medical need. As we expand the scope of our internal drug discovery and development efforts, we look forward to continuing to enter partnerships with leading innovators to create new therapeutic options for patients.”
More information on Confo Therapeutics' website.